Introduction
============

Influenza vaccination is the primary strategy to prevent influenza-related morbidity and mortality, especially for older adults, who are at higher risk of severe outcomes \[[@r1]\]. In this age group, influenza vaccines are 24--63% effective in preventing laboratory-confirmed influenza \[[@r2]-[@r4]\]. Due to frequent changes in circulating virus strains, annual vaccination is recommended.

However, the impact of repeated vaccination on vaccine effectiveness (VE) is uncertain. A randomised trial (RCT) conducted in the 1970s at a British boarding school found higher influenza incidence among students who had received multiple previous vaccines than among those who received only the current season's vaccine \[[@r5]\]. Results from a larger RCT among adults in the 1980s did not lead to the same conclusion \[[@r6]\]. Based on the antigenic distance hypothesis put forth by Smith et al., negative or positive interference can result from prior season vaccination depending on differences in the antigenic distances between prior and current vaccine strains and the current epidemic strain \[[@r7]\]. Most studies to date incorporated only a single previous season when examining the impact of repeated vaccination \[[@r8]-[@r13]\]. Meta-analyses of these studies found substantial heterogeneity in repeated vaccination effects \[[@r14]-[@r16]\].

Two studies examined the impact of repeated vaccination for five previous seasons. Whereas McLean et al. observed current season VE to be higher in those who were not vaccinated in any of the previous five seasons compared with those who were vaccinated in all five previous seasons \[[@r17]\], Örtqvist et al. found no negative effect of repeated vaccination \[[@r18]\]. Thus, the effect of repeated vaccination beyond one previous season also remains unclear. This is of particular interest for older adults because not only do they bear the greatest burden of disease, but they are also recommended to receive the vaccine annually in most countries and therefore may have received many doses.

The objectives of this study were to estimate VE against laboratory-confirmed influenza infection in community-dwelling older adults for the 2010/11 to 2015/16 seasons and to investigate the impact of repeated vaccination for up to 10 previous seasons on current season VE.

Methods
=======

Study population, setting, and design
-------------------------------------

We studied community-dwelling adults aged \> 65 years in Ontario (2016 population aged ≥ 65 years: 2.3 million) who were tested for influenza during inpatient or outpatient healthcare encounters between 1 September 2010 and 31 August 2016. Details regarding these six influenza seasons have been reported previously \[[@r19]\]. We used personal identifiers (health card number, name, date of birth, sex, postal code) and a combination of deterministic and probabilistic methods to link the results of respiratory virus tests performed by a network of 19 public health and academic hospital laboratories to population-based provincial health administrative data (linkage proportion = 97.8%) \[[@r19]\]. These datasets were linked using unique coded identifiers and analysed at ICES (formerly the Institute for Clinical Evaluative Sciences). All patients had universal access to physician services, hospital care, diagnostic testing, prescription medications, and trivalent influenza vaccines during the study.

We estimated VE using the test-negative design, which compares the odds of influenza vaccination among laboratory-confirmed influenza cases and test-negative controls \[[@r20]\].

Ethical statement
-----------------

Ethics approval for this study was obtained from the participating laboratories ([Supplementary Table S1](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). The planning, conduct, and reporting of this study was in line with the Declaration of Helsinki.

Data sources and definitions
----------------------------

### Laboratory data

We included the results of all respiratory virus tests conducted by participating laboratories. The laboratories used monoplex and multiplex PCR assays, viral culture, direct immunofluorescence assay, or enzyme immunoassay tests to test for one or more of the following viruses: adenovirus, bocavirus, coronavirus, enterovirus/rhinovirus, human metapneumovirus, influenza A, influenza B, parainfluenza virus, and respiratory syncytial virus \[[@r19]\]. We combined the results of all specimens for the same individual on the same day into a single testing episode. For participants tested multiple times in the same season, we included their earliest testing episode positive for influenza (or their earliest testing episode if all specimens tested negative for influenza) for analysis. Individuals tested in multiple seasons contributed one testing episode per season, which were treated as separate units in the analysis. Specimens were submitted at the discretion of clinicians as part of routine clinical care. The proportion of patients presenting with acute respiratory illnesses (ARI) who were tested for influenza varied by setting (22.1% for inpatients, 2.5% for patients in emergency departments, and 2.3% for patients in physician offices) \[[@r19]\].

Since only 49% of individuals positive for influenza A had their specimens subtyped, we assessed their generalisability by comparing the characteristics of those with subtyped and unsubtyped influenza A specimens ([Supplementary Table S2](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). Information on lineage for influenza B was not available.

### Healthcare encounter data

We identified all healthcare encounters associated with a specimen on the date of collection using the Canadian Institute for Health Information's Discharge Abstract Database (CIHI-DAD), the National Ambulatory Care Reporting System (NACRS) database, and the Ontario Health Insurance Plan (OHIP) database. The proportion of missing data in each of the healthcare use databases should be very low since healthcare is universally covered for those with provincial health insurance.

### Influenza vaccination

We ascertained influenza vaccination status using physician and (starting in 2012, when a policy change permitted pharmacists to administer influenza vaccines) pharmacist billing claims, maintained in the OHIP and Ontario Drug Benefit (ODB) databases, respectively. For VE calculations, participants were considered immunised if a vaccine dose was received ≥ 14 days before the specimen collection date.

### Covariates

We obtained demographic information including age, sex, and census area-level neighbourhood income quintile through the Ontario Registered Persons Database. Healthcare use information including the number of hospitalisations in the past 3 years, outpatient visits in the past year, receipt of home care services in the past year, and prescription medications in the past year were determined using CIHI-DAD, OHIP, Home Care Database, and ODB, respectively. We determined the presence of comorbidities that increase the risk of influenza complications (anaemia, cancer, cardiovascular disease, dementia, diabetes, frailty, immunodeficiency due to underlying disease and/or therapy, as well as renal disease and respiratory disease) based on the presence of these diagnoses in various databases before the date of specimen collection \[[@r19]\].

Statistical analysis
--------------------

### Vaccine effectiveness

We used logistic regression to estimate VE, against laboratory-confirmed influenza infection, by comparing the odds of vaccination in the test-positive cases to the odds of vaccination in the test-negative controls through an odds ratio (OR) and using the following formula VE = (1 − OR) × 100%. The models controlled for the demographic characteristics and measures of previous healthcare use listed above, presence of any comorbidity, calendar time (month of test), and influenza season (except when estimating VE by season). These variables were selected a priori and were included because of their clinical importance and conceptualisation as potential confounders. We used a threshold level of 5% test positivity for the province to restrict the analyses to periods when influenza was circulating.

We estimated VE against any influenza and each influenza type/subtype for the 2010/11 to 2015/16 seasons combined and for each season separately. We also performed subgroup analyses by age group, sex, and healthcare setting, and used interaction tests to assess whether VE differed by subgroup.

We conducted a number of sensitivity analyses. First, we restricted the cohort to patients who had a diagnostic code for an ARI \[[@r19]\] for their healthcare encounter, to emulate case definitions used in prospective test-negative studies. Second, we restricted the cohort to patients who were tested by PCR. Third, since Ontario residents may receive influenza vaccines in settings besides physician offices and pharmacies (leading to incorrectly classifying individuals vaccinated outside of these settings as unvaccinated), for each of the above analyses we conducted a quantitative sensitivity analysis using a publicly available macro \[[@r21]\] to correct for misclassification of influenza vaccination status using previously reported parameters for sensitivity (69%) and specificity (90%) of influenza vaccination codes for older adults in Ontario health administrative databases \[[@r22]\]. This macro performs multiple iterations of exposure re-classification for each execution. For each iteration, sensitivity and specificity values within the 95% confidence interval (CI) of the previously reported parameters are selected. Using these values and the observed counts of exposed cases and controls, expected counts are determined to calculate a positive predictive value (PPV) and negative predictive value (NPV) for cases and controls separately. PPV is the probability that the individual was correctly classified as exposed, whereas NPV is the probability that an individual was correctly classified as unexposed. For each individual, a random number is chosen from a uniform distribution between 0 and 1, and compared with the predictive value based on their case and exposure statuses. If the random number is greater than the predictive value, the subject is reclassified \[[@r21]\]. An OR is calculated using the reclassified exposure value for each iteration, and the median OR from the distribution of ORs from all iterations is reported \[[@r21]\]. This macro does not permit incorporation of interaction terms with the main exposure to do an interaction test between subgroups.

### Impact of repeated vaccination on current season vaccine effectiveness

Next, we examined the impact of repeated vaccination on current season VE against any influenza and each influenza type/subtype for the 2010/11 to 2015/16 seasons combined. We did this taking into account incrementally longer vaccination history durations (i.e. one, five, and 10 previous influenza seasons). Since influenza vaccination data in Ontario are more accurate among those aged ≥ 65 years \[[@r22]\], we restricted the analysis examining 5-year vaccination history to patients aged ≥ 70 years in the current season to ensure they were ≥ 65 years for all previous seasons. Similarly, we restricted the analysis examining 10-year vaccination history to patients aged ≥ 75 years in the current season. Patients had to be eligible for health insurance in Ontario during the previous seasons investigated.

For each analysis, we stratified the study population based on individuals' vaccination history (i.e. number of previous vaccinations received) and we estimated current season VE conditioned on vaccination history. Therefore, the reference group for estimating VE is patients who share similar vaccination histories as those who are vaccinated in the current season but are unvaccinated in the current season. For example, we compared patients who had received 9--10 previous vaccinations and who were vaccinated in the current season to those who had received 9--10 previous vaccinations but who were not vaccinated in the current season. The rationale for this approach is that it quantifies the incremental benefit of vaccination in the current season, and acknowledges that since a patient cannot change his/her past vaccination status, comparing to those not vaccinated in the current nor any past season may not be appropriate. Ultimately, this provides more patient-centred results as it aligns with the decision that needs to be made by patients each season regarding the benefit of receiving the current season's vaccine.

We used interaction tests to assess differences in current season VE estimates between those vaccinated in the prior season and those not vaccinated in the prior season. For previous vaccination histories of five and 10 seasons, we used meta-regression to assess for trends in VE estimates between the vaccination history strata \[[@r23]\].

In sensitivity analyses, we corrected for misclassification of current season vaccination status. For the macro programme to successfully execute, we assumed the same values of sensitivity and specificity for all strata of past vaccination history. We repeated the analyses restricted to patients aged ≥ 75 years in the current season for greater consistency of the VE estimates across the varying vaccination history durations. We also conducted sensitivity analyses in which we manually reclassified past vaccination status for those who were misclassified for the current season based on the macro programme (details in [Supplementary Text](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). In the first scenario, we changed vaccination status from unvaccinated to vaccinated for all previous seasons, effectively moving all misclassified individuals into the most vaccinated category in terms of vaccination history. In the second scenario, we moved individuals 'up' a single category (e.g. for the analysis examining 5-year vaccination history, those initially considered vaccinated in none of the previous five seasons were re-categorised to the 'vaccinated in 1--3 of the previous five seasons' group).

To facilitate comparisons with previous studies, we repeated these analyses using the conventional approach of estimating VE for all combinations of vaccine exposure in the current and previous seasons against a common reference group of patients who were not vaccinated in the current season and any previous seasons under consideration. To assess for trend with this approach, we included the parameterised vaccination history variable as a continuous variable in the model \[[@r24]\].

### Analysis tools and statistical significance

Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.4.0 (R Core Team, Vienna, Austria). All tests were two-sided and used p *\<* 0.05 as the level of statistical significance.

Results
=======

We included 58,304 testing episodes (obtained from 54,116 unique patients, including 7% tested during multiple seasons), with 11,496 (20%) testing positive for influenza and 31,004 (53%) vaccinated during the season of testing and before specimen collection. Compared with test-negative controls, test-positive cases were older, were more likely to be female, used fewer health services, had fewer comorbidities, and were less likely to be vaccinated ([Supplementary Table S3](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). Descriptive statistics comparing vaccinated and unvaccinated patients can be found in [Supplementary Table S4](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data).

Overall adjusted VE against any influenza for the 2010/11 to 2015/16 seasons combined was 21% (95%CI: 18 to 24%) ([**Table 1**](#t1){ref-type="table"}). For the six seasons combined, VE was 38% (95%CI: 28 to 46%) against A(H1N1)pdm09, 22% (95%CI: 16 to 28%) against A(H3N2), and 30% (95%CI: 24 to 36%) against B. VE against unsubtyped influenza A viruses was only 11% (95%CI: 5 to 16%). We observed substantial variability in VE by season (interaction test p \< 0.001), by age group (p = 0.01), and by sex (p = 0.03), but not by healthcare setting (p = 0.60). After correcting for misclassification of vaccination status, VE for the six seasons combined increased to 38% (95%CI: 35 to 42%) against any influenza. We observed similar results when restricting the analysis to ARI-coded healthcare encounters and to patients tested by PCR ([**Table 1**](#t1){ref-type="table"}). VE estimates stratified by influenza subtype and season are presented in [Supplementary Table S5](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data).

###### Influenza vaccine effectiveness estimates for community-dwelling adults aged \> 65 years, 2010/11 to 2015/16 influenza seasons in Ontario, Canada (n = 58,304)^a^

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analysis                    Test-positive patients\   Test-negative patients\   Unadjusted VE% (95% CI)   Adjusted VE% (95% CI)   Misclassification corrected\   
                              No. vaccinated/total      No. vaccinated/total                                                        Adjusted VE% (95% CI)          
  --------------------------- ------------------------- ------------------------- ------------------------- ----------------------- ------------------------------ ---------------
  Overall^b^                  5,575/11,496              25,429/46,808             21 (18 to 24)             21 (18 to 24)           38 (35 to 42)                  

  By influenza type/subtype                                                                                                                                        

  Influenza A^c^              A(H3N2)                   1,780/3,765               25,429/46,808             25 (19 to 29)           22 (16 to 28)                  44 (38 to 49)

  A(H1N1)pdm09                347/830                   25,429/46,808             40 (31 to 47)             38 (28 to 46)           61 (53 to 68)                  

  A(unsubtyped)               2,425/4,772               25,429/46,808             13 (8 to 18)              11 (5 to 16)            25 (18 to 31)                  

  Influenza B                 1,027/2,138               25,429/46,808             22 (15 to 29)             30 (24 to 36)           42 (37 to 49)                  

  By influenza season                                                                                                                                              

  2010/11                     488/1,204                 2,561/4,980               36 (27 to 43)             33 (23 to 41)           54 (45 to 61)                  

  2011/12                     195/413                   1,823/3,216               32 (16 to 44)             32 (16 to 45)           54 (34 to 66)                  

  2012/13                     988/2,253                 4,339/8,577               24 (16 to 31)             20 (12 to 28)           38 (29 to 45)                  

  2013/14                     711/1,554                 5,368/9,665               32 (25 to 39)             36 (28 to 42)           56 (49 to 62)                  

  2014/15                     2,416/4,432               6,712/12,044              5 (−2 to 11)              6 (−1 to 13)            12 (2 to 21)                   

  2015/16                     777/1,640                 4,626/8,326               28 (20 to 35)             26 (17 to 34)           49 (40 to 56)                  

  By age group in years                                                                                                                                            

  66--75                      1,525/3,601               8,387/16,716              27 (22 to 32)             28 (22 to 33)           42 (34 to 49)                  

  76--85                      2,328/4,548               10,402/18,181             22 (16 to 27)             20 (14 to 25)           42 (36 to 48)                  

  ≥ 86                        1,722/3,347               6,640/11,911              16 (9 to 22)              13 (5 to 20)            31 (22 to 38)                  

  By sex                                                                                                                                                           

  Male                        2,611/5,348               12,470/22,446             24 (19 to 28)             25 (21 to 30)           44 (38 to 49)                  

  Female                      2,964/6,148               12,959/24,362             18 (13 to 23)             17 (12 to 22)           34 (28 to 40)                  

  By healthcare setting                                                                                                                                            

  Inpatient                   4,460/9,224               22,424/41,178             22 (18 to 25)             21 (18 to 25)           40 (35 to 44)                  

  Outpatient                  1,146/2,330               3,398/6,368               15 (7 to 23)              18 (10 to 26)           30 (20 to 39)                  

  ARI-coded encounter         5,068/10,459              16,968/31,185             21 (18 to 25)             21 (18 to 25)           39 (35 to 43)                  

  Tested by PCR^d^            4,741/9,841               19,586/35,877             23 (19 to 26)             22 (18 to 26)           41 (37 to 45)                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARI: acute respiratory illness; CI: confidence interval; No.: number; NA: not applicable; VE: vaccine effectiveness.

**^a^** The model adjusted for age, sex, census area-level neighbourhood income quintile, number of hospitalisations in the past 3 years, number of outpatient visits in the past year, receipt of home care services in the past year, number of prescription medications in the past year, comorbidities that increase the risk of influenza complications (anaemia, cancer, cardiovascular disease, dementia, diabetes, frailty, immunodeficiency due to underlying disease and/or therapy, as well as renal disease and respiratory disease), calendar time, and influenza season.

**^b^** For any influenza, 2010/11 to 2015/16 influenza seasons combined.

**^c^** Only 49% of influenza A specimens were subtyped.

**^d^** PCR (monoplex or multiplex).

Impact of repeated vaccination on vaccine effectiveness
-------------------------------------------------------

Patients who had received more vaccinations in previous seasons were older and more likely to be male, use health services, and have comorbidities, although the magnitudes of the differences between groups were small ([**Table 2**](#t2){ref-type="table"}, [**Table 3**](#t3){ref-type="table"}, [**Table 4**](#t4){ref-type="table"}). Current season adjusted VE was higher for patients not vaccinated in the previous season (28%; 95%CI: 23 to 34%) than for those who were vaccinated in the previous season (9%; 95%CI: 3 to 14%) (interaction test p \< 0.001) ([**Figure 1a**](#f1){ref-type="fig"}). In the analysis accounting for 5-year vaccination history, patients who had received no vaccinations in the previous five seasons had the highest VE for current season vaccination (37%; 95%CI: 22 to 48%), with lower but still significant VE estimates for patients who had received 1--3 (20%; 95%CI: 13 to 26%) and 4--5 (10%; 95%CI: 3 to 17%) vaccinations in the previous five seasons (trend test p = 0.001). Similar results were observed when accounting for 10-year vaccination history: patients who had received no vaccinations in the previous 10 seasons had the highest VE for current season vaccination (34%; 95%CI: 9 to 52%), with VE decreasing with more previous vaccinations received over the previous 10 seasons: 26% (95%CI: 13 to 37%) for those vaccinated 1--3 times, 24% (95%CI: 15 to 33%) for those vaccinated 4--6 times, 13% (95%CI: 2 to 22%) for those vaccinated 7--8 times, and 7% (95%CI: −4 to 16%) for those vaccinated 9--10 times (trend test p = 0.001).

###### Descriptive characteristics of community-dwelling adults aged \> 65 years for the 2010/11 to 2015/16 influenza seasons, stratified by vaccination history for the previous season, Ontario, Canada (n = 58,021)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                   Total\         Vaccinated in previous season\   Not vaccinated in previous season\   p value                        
                                                   (n = 58,021)   (n = 33,243)                     (n = 24,778)                                                        
  ------------------------------------------------ -------------- -------------------------------- ------------------------------------ --------- ------------- ------ ----------
  Influenza season                                                                                                                                                     

  2010/11                                          6,162          10.6                             3,678                                11.1      2,484         10.0   \< 0.001

  2011/12                                          3,607          6.2                              2,081                                6.3       1,526         6.2    

  2012/13                                          10,777         18.6                             5,874                                17.7      4,903         19.8   

  2013/14                                          11,145         19.2                             6,079                                18.3      5,066         20.4   

  2014/15                                          16,411         28.3                             9,743                                29.3      6,668         26.9   

  2015/16                                          9,919          17.1                             5,788                                17.4      4,131         16.7   

  Age (years), mean ± SD                           79.6 ± 8.2     NA                               80.1 ± 8.0                           NA        78.8 ± 8.4    NA     \< 0.001

  Age group in years                                                                                                                                                   

  66--75                                           20,192         34.8                             10,495                               31.6      9,697         39.1   \< 0.001

  76--85                                           22,617         39.0                             13,588                               40.9      9,029         36.4   

  ≥ 86                                             15,212         26.2                             9,160                                27.6      6,052         24.4   

  Male sex                                         27,660         47.7                             16,139                               48.5      11,521        46.5   \< 0.001

  Neighbourhood income quintile                                                                                                                                        

  1 (lowest)                                       13,044         22.5                             7,113                                21.4      5,931         23.9   \< 0.001

  2                                                12,321         21.2                             7,112                                21.4      5,209         21.0   

  3                                                10,935         18.8                             6,300                                19.0      4,635         18.7   

  4                                                10,341         17.8                             6,001                                18.1      4,340         17.5   

  5 (highest)                                      11,026         19.0                             6,540                                19.7      4,486         18.1   

  Missing                                          354            0.6                              177                                  0.5       177           0.7    

  Medical conditions                                                                                                                                                   

  Cardiovascular disease^a^                        37,212         64.1                             21,778                               65.5      15,434        62.3   \< 0.001

  Chronic obstructive pulmonary disease            29,672         51.1                             17,734                               53.3      11,938        48.2   \< 0.001

  Diabetes                                         24,858         42.8                             14,594                               43.9      10,264        41.4   \< 0.001

  Cancer                                           17,082         29.4                             10,167                               30.6      6,915         27.9   \< 0.001

  Asthma                                           16,179         27.9                             9,948                                29.9      6,231         25.1   \< 0.001

  Anaemia                                          13,988         24.1                             8,384                                25.2      5,604         22.6   \< 0.001

  Chronic kidney disease                           12,853         22.2                             7,456                                22.4      5,397         21.8   0.063

  Dementia/frailty                                 11,410         19.7                             6,481                                19.5      4,929         19.9   0.23

  Immunocompromised                                8,185          14.1                             4,983                                15.0      3,202         12.9   \< 0.001

  Any of the above medical conditions              55,351         95.4                             32,009                               96.3      23,342        94.2   \< 0.001

  Received homecare services, past 1y              28,321         48.8                             16,098                               48.4      12,223        49.3   0.03

  Hospitalisations, past 3y, mean ± SD             1.6 ± 2.2      NA                               1.6 ± 2.1                            NA        1.6 ± 2.3     NA     \< 0.001

  Outpatient visits, past 1y, mean ± SD            14.2 ± 11.0    NA                               15.5 ± 11.0                          NA        12.5 ± 10.7   NA     \< 0.001

  Prescription medications, past 1y, mean ± SD     16.5 ± 9.3     NA                               17.4 ± 9.1                           NA        15.4 ± 9.5    NA     \< 0.001

  Month of influenza testing                                                                                                                                           

  November                                         1,407          2.4                              785                                  2.4       622           2.5    0.83

  December                                         9,486          16.3                             5,402                                16.3      4,084         16.5   

  January                                          15,038         25.9                             8,605                                25.9      6,433         26.0   

  February                                         10,304         17.8                             5,904                                17.8      4,400         17.8   

  March                                            10,686         18.4                             6,166                                18.5      4,520         18.2   

  April                                            7,599          13.1                             4,378                                13.2      3,221         13.0   

  May                                              3,501          6.0                              2,003                                6.0       1,498         6.0    

  Tested sample from inpatient setting             49,621         85.5                             28,544                               85.9      21,077        85.1   0.007

  Specimen positive for influenza                  11,444         19.7                             6,177                                18.6      5,267         21.3   \< 0.001

  Vaccinated against influenza in current season   30,916         53.3                             24,592                               74.0      6,324         25.5   \< 0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not applicable; SD: standard deviation.

**^a^** Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischaemic heart disease, and transient ischaemic attack.

###### Descriptive characteristics of community-dwelling adults aged ≥ 70 years for the 2010/11 to 2015/16 influenza seasons, stratified by influenza vaccination history over five previous seasons, Ontario, Canada (n = 49,294)

  Characteristic                                   Vaccination history over five previous seasons                                                                        
  ------------------------------------------------ ------------------------------------------------ ------ ------------- ------ ------------- ------ ------------ ------ ----------
  Influenza season                                                                                                                                                       
  2010/11                                          5,295                                            10.7   2,656         10.8   1,700         10.7   939          10.8   0.05
  2011/12                                          3,046                                            6.2    1,589         6.4    932           5.8    525          6.0    
  2012/13                                          9,216                                            18.7   4,563         18.5   3,023         19.0   1,630        18.7   
  2013/14                                          9,328                                            18.9   4,609         18.7   3,011         18.9   1,708        19.6   
  2014/15                                          14,192                                           28.8   7,178         29.1   4,618         29.0   2,396        27.5   
  2015/16                                          8,217                                            16.7   4,069         16.5   2,649         16.6   1,499        17.2   
  Age (years), mean ± SD                           81.5 ± 7.1                                       NA     82.1 ± 6.9    NA     81.3 ± 7.2    NA     80.3 ± 7.1   NA     \< 0.001
  Age group in years                                                                                                                                                     
  70--75                                           11,952                                           24.2   5,058         20.5   4,191         26.3   2,703        31.1   \< 0.001
  76--85                                           22,290                                           45.2   11,553        46.8   6,963         43.7   3,774        43.4   
  ≥ 86                                             15,052                                           30.5   8,053         32.7   4,779         30.0   2,220        25.5   
  Male sex                                         23,256                                           47.2   11,936        48.4   7,386         46.4   3,934        45.2   \< 0.001
  Neighbourhood income quintile                                                                                                                                          
  1 (lowest)                                       10,872                                           22.1   5,102         20.7   3,652         22.9   2,118        24.4   \< 0.001
  2                                                10,485                                           21.3   5,349         21.7   3,316         20.8   1,820        20.9   
  3                                                9,356                                            19.0   4,690         19.0   3,068         19.3   1,598        18.4   
  4                                                8,829                                            17.9   4,458         18.1   2,824         17.7   1,547        17.8   
  5 (highest)                                      9,470                                            19.2   4,934         20.0   2,994         18.8   1,542        17.7   
  Missing                                          282                                              0.6    131           0.5    79            0.5    72           0.8    
  Medical conditions                                                                                                                                                     
  Cardiovascular disease^a^                        32,830                                           66.6   16,841        68.3   10,610        66.6   5,379        61.8   \< 0.001
  Chronic obstructive pulmonary disease            25,351                                           51.4   13,214        53.6   8,329         52.3   3,808        43.8   \< 0.001
  Diabetes                                         21,154                                           42.9   10,910        44.2   6,850         43.0   3,394        39.0   \< 0.001
  Cancer                                           14,559                                           29.5   7,563         30.7   4,682         29.4   2,314        26.6   \< 0.001
  Asthma                                           13,725                                           27.8   7,561         30.7   4,381         27.5   1,783        20.5   \< 0.001
  Anaemia                                          12,090                                           24.5   6,375         25.8   3,899         24.5   1,816        20.9   \< 0.001
  Chronic kidney disease                           11,272                                           22.9   5,706         23.1   3,804         23.9   1,762        20.3   \< 0.001
  Dementia/frailty                                 10,845                                           22.0   5,345         21.7   3,877         24.3   1,623        18.7   \< 0.001
  Immunocompromised                                6,463                                            13.1   3,433         13.9   2,060         12.9   970          11.2   \< 0.001
  Any of the above medical conditions              47,310                                           96.0   23,877        96.8   15,335        96.2   8,098        93.1   \< 0.001
  Received homecare services, past 1y              25,184                                           51.1   12,567        51.0   8,456         53.1   4,161        47.8   \< 0.001
  Hospitalisations, past 3y, mean ± SD             1.6 ± 2.1                                        NA     1.5 ± 2.1     NA     1.7 ± 2.3     NA     1.4 ± 2.1    NA     \< 0.001
  Outpatient visits, past 1y, mean ± SD            14.0 ± 10.7                                      NA     15.5 ± 10.7   NA     13.3 ± 10.6   NA     11.0 ± 9.9   NA     \< 0.001
  Prescription medications, past 1y, mean ± SD     16.6 ± 9.1                                       NA     17.5 ± 8.8    NA     16.8 ± 9.2    NA     13.7 ± 9.0   NA     \< 0.001
  Month of influenza testing                                                                                                                                             
  November                                         1,178                                            2.4    590           2.4    380           2.4    208          2.4    0.74
  December                                         8,127                                            16.5   4,111         16.7   2,592         16.3   1,424        16.4   
  January                                          12,920                                           26.2   6,376         25.9   4,250         26.7   2,294        26.4   
  February                                         8,741                                            17.7   4,346         17.6   2,813         17.7   1,582        18.2   
  March                                            9,009                                            18.3   4,533         18.4   2,939         18.4   1,537        17.7   
  April                                            6,398                                            13.0   3,237         13.1   2,024         12.7   1,137        13.1   
  May                                              2,921                                            5.9    1,471         6.0    935           5.9    515          5.9    
  Tested sample from inpatient setting             42,652                                           86.5   21,487        87.1   13,767        86.4   7,398        85.1   \< 0.001
  Specimen positive for influenza                  9,877                                            20.0   4,743         19.2   3,117         19.6   2,017        23.2   \< 0.001
  Vaccinated against influenza in current season   27,043                                           54.9   18,946        76.8   7,325         46.0   772          8.9    \< 0.001

NA: not applicable; SD: standard deviation.

**^a^** Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischaemic heart disease, and transient ischaemic attack.

###### Descriptive characteristics of community-dwelling adults aged ≥ 75 years for the 2010/11 to 2015/16 influenza seasons, stratified by influenza vaccination history over 10 previous seasons, Ontario, Canada (n = 38,766)

  Characteristic                                   Vaccination history over 10 previous seasons                                                                                                                  
  ------------------------------------------------ ---------------------------------------------- ------ ------------- ------ ------------- ------ ------------- ------ ------------- ------ ------------ ------ ----------
  Influenza season                                                                                                                                                                                               
  2010/11                                          4,144                                          10.7   1,268         9.7    1,024         11.4   852           11.5   539           10.5   461          11.1   0.02
  2011/12                                          2,371                                          6.1    835           6.4    552           6.1    442           6.0    297           5.8    245          5.9    
  2012/13                                          7,294                                          18.8   2,430         18.6   1,702         18.9   1,407         19.0   948           18.4   807          19.4   
  2013/14                                          7,254                                          18.7   2,470         18.9   1,663         18.5   1,363         18.4   974           18.9   784          18.9   
  2014/15                                          11,416                                         29.4   3,953         30.3   2,595         28.8   2,133         28.8   1,552         30.2   1,183        28.4   
  2015/16                                          6,287                                          16.2   2,080         16.0   1,472         16.3   1,219         16.4   837           16.3   679          16.3   
  Age (years), mean ± SD                           83.9 ± 5.8                                     NA     84.4 ± 5.7    NA     84.3 ± 5.8    NA     83.6 ± 5.8    NA     83.2 ± 5.8    NA     83.1 ± 5.9   NA     \< 0.001
  Age group in years                                                                                                                                                                                             
  75                                               2,011                                          5.2    509           3.9    410           4.6    442           6.0    343           6.7    307          7.4    \< 0.001
  76--85                                           21,900                                         56.5   7,149         54.8   4,943         54.9   4,273         57.6   3,056         59.4   2,479        59.6   
  ≥ 86                                             14,855                                         38.3   5,378         41.3   3,655         40.6   2,701         36.4   1,748         34.0   1,373        33.0   
  Male sex                                         17,936                                         46.3   6,291         48.3   4,060         45.1   3,408         46.0   2,358         45.8   1,819        43.7   \< 0.001
  Neighbourhood income quintile                                                                                                                                                                                  
  1 (lowest)                                       8,338                                          21.5   2,592         19.9   1,883         20.9   1,664         22.4   1,194         23.2   1,005        24.2   \< 0.001
  2                                                8,264                                          21.3   2,846         21.8   1,876         20.8   1,588         21.4   1,090         21.2   864          20.8   
  3                                                7,328                                          18.9   2,509         19.2   1,695         18.8   1,410         19.0   1,007         19.6   707          17.0   
  4                                                6,988                                          18.0   2,350         18.0   1,671         18.6   1,321         17.8   889           17.3   757          18.2   
  5 (highest)                                      7,618                                          19.7   2,661         20.4   1,841         20.4   1,396         18.8   942           18.3   778          18.7   
  Missing                                          230                                            0.6    78            0.6    42            0.5    37            0.5    25            0.5    48           1.2    
  Medical conditions                                                                                                                                                                                             
  Cardiovascular disease^a^                        26,959                                         69.5   9,175         70.4   6,453         71.6   5,230         70.5   3,415         66.3   2,686        64.6   \< 0.001
  Chronic obstructive pulmonary disease            19,818                                         51.1   6,819         52.3   4,809         53.4   3,935         53.1   2,537         49.3   1,718        41.3   \< 0.001
  Diabetes                                         16,241                                         41.9   5,634         43.2   3,889         43.2   3,115         42.0   2,096         40.7   1,507        36.2   \< 0.001
  Cancer                                           11,339                                         29.2   4,011         30.8   2,655         29.5   2,185         29.5   1,409         27.4   1,079        25.9   \< 0.001
  Asthma                                           10,623                                         27.4   3,896         29.9   2,671         29.7   2,042         27.5   1,229         23.9   785          18.9   \< 0.001
  Anaemia                                          9,559                                          24.7   3,428         26.3   2,309         25.6   1,764         23.8   1,181         22.9   877          21.1   \< 0.001
  Chronic kidney disease                           9,040                                          23.3   2,997         23.0   2,241         24.9   1,833         24.7   1,145         22.2   824          19.8   \< 0.001
  Dementia/frailty                                 9,795                                          25.3   3,129         24.0   2,494         27.7   2,022         27.3   1,298         25.2   852          20.5   \< 0.001
  Immunocompromised                                4,514                                          11.6   1,551         11.9   1,124         12.5   937           12.6   529           10.3   373          9.0    \< 0.001
  Any of the above medical conditions              37,380                                         96.4   12,645        97.0   8,743         97.1   7,182         96.8   4,927         95.7   3,883        93.4   \< 0.001
  Received homecare services, past 1y              21,006                                         54.2   6,947         53.3   5,087         56.5   4,148         55.9   2,734         53.1   2,090        50.3   \< 0.001
  Hospitalisations, past 3y, mean ± SD             1.5 ± 2.1                                      NA     1.5 ± 1.9     NA     1.7 ± 2.2     NA     1.7 ± 2.2     NA     1.6 ± 2.1     NA     1.3 ± 1.8    NA     \< 0.001
  Outpatient visits, past 1y, mean ± SD            13.7 ± 10.3                                    NA     15.3 ± 10.3   NA     14.2 ± 10.4   NA     13.1 ± 10.3   NA     12.0 ± 10.0   NA     10.5 ± 9.3   NA     \< 0.001
  Prescription medications, past 1y, mean ± SD     16.5 ± 8.8                                     NA     17.2 ± 8.5    NA     17.4 ± 8.8    NA     16.8 ± 9.0    NA     15.4 ± 8.8    NA     13.1 ± 8.8   NA     \< 0.001
  Month of influenza testing                                                                                                                                                                                     
  November                                         908                                            2.3    286           2.2    232           2.6    161           2.2    146           2.8    83           2.0    0.27
  December                                         6,426                                          16.6   2,226         17.1   1,479         16.4   1,217         16.4   834           16.2   670          16.1   
  January                                          10,301                                         26.6   3,412         26.2   2,352         26.1   2,041         27.5   1,364         26.5   1,132        27.2   
  February                                         6,853                                          17.7   2,263         17.4   1,620         18.0   1,300         17.5   924           18.0   746          17.9   
  March                                            7,036                                          18.1   2,352         18.0   1,672         18.6   1,346         18.1   930           18.1   736          17.7   
  April                                            4,976                                          12.8   1,694         13.0   1,152         12.8   930           12.5   654           12.7   546          13.1   
  May                                              2,266                                          5.8    803           6.2    501           5.6    421           5.7    295           5.7    246          5.9    
  Tested sample from inpatient setting             33,904                                         87.5   11,474        88.0   7,875         87.4   6,511         87.8   4,449         86.4   3,595        86.4   0.01
  Specimen positive for influenza                  8,043                                          20.7   2,653         20.4   1,783         19.8   1,502         20.3   1,095         21.3   1,010        24.3   \< 0.001
  Vaccinated against influenza in current season   21,645                                         55.8   10,297        79.0   5,847         64.9   3,768         50.8   1,450         28.2   283          6.8    \< 0.001

NA: not applicable; SD: standard deviation.

**^a^** Includes acute ischaemic stroke, arrhythmias, congestive heart failure, ischemic heart disease, and transient ischaemic attack.
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We observed similar trends against A(H3N2) ([Supplementary Figure S1](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)) but not against A(H1N1)pdm09 ([Supplementary Figure S2](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)) or influenza B ([Supplementary Figure S3](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)).

When correcting for misclassification of current season vaccination status, we found similar patterns as the primary analysis, but with VE estimates that were higher in magnitude ([**Figure 1b**](#f1){ref-type="fig"}). Repeating the analyses restricted to patients aged ≥ 75 years in the current season, the patterns were similar to our primary analysis, but the VE estimates were slightly lower ([Supplementary Figure S4a](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). After correcting for misclassification of current season vaccination status within this restricted cohort, VE estimates were higher but the overall trends were consistent ([Supplementary Figure S4b](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). Results were similar when manually reclassifying vaccination status in past seasons based on current season misclassification ([Supplementary Figure S5](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)).

Using the conventional approach of comparing to a common reference group, VE did not differ substantially for patients vaccinated in both prior and current seasons (25%; 95%CI: 22 to 29%) and those vaccinated in the current season only (29%; 95%CI: 23 to 34%) (interaction test p = 0.31), but was lower for those vaccinated in the prior season only (18%; 95%CI: 13 to 23%) (p \< 0.001) ([Supplementary Figure S6](/content/10.2807/1560-7917.ES.2020.25.1.1900245#supplementary_data)). When accounting for 5-year vaccination history, significant protection against influenza was observed among patients with any previous vaccination, with or without current season vaccination. Notably, for similar levels of vaccination in previous seasons, receipt of current season vaccination was associated with higher VE estimates than being unvaccinated in the current season. VE decreased for current vaccine recipients as the number of previous vaccinations received increased (i.e. 36% vs 31% vs 26%) (trend test p = 0.007). In contrast, for those not vaccinated in the current season, residual protection increased as the number of previous vaccinations received increased (i.e. 13% vs 17%) (p \< 0.001). Similar patterns were observed when considering 10-year vaccination history, with VE decreasing for current vaccine recipients with increasing numbers of previous vaccinations (from 33% to 22%) (p \< 0.001), while the opposite trend in residual protection was observed for those without current season vaccination (from 9% to 16%) (p \< 0.001).

Discussion
==========

In this study of older adults, we estimated VE against laboratory-confirmed influenza healthcare use to be 21% (95%CI: 18 to 24%) during the 2010/11 to 2015/16 influenza seasons, which increased to 38% (95%CI: 35 to 42%) after correcting for misclassification of vaccination status. When we examined the impact of repeated vaccination during previous influenza seasons on VE for the current season, we observed a declining trend in VE as the number of previous vaccinations increased. Nevertheless, influenza vaccination during the current season was associated with some protection against influenza infection irrespective of the number of vaccinations over the previous 10 seasons, except for individuals vaccinated 9--10 times before we corrected for misclassification of vaccination status. After correcting for misclassification of vaccination status in the current season, influenza vaccination was associated with some protection even for those vaccinated 9--10 times during the previous 10 seasons. Reassuringly, the overall observed trends in VE were consistent when correcting for this misclassification, both for the current season only and when manually reclassifying vaccination status during past seasons based on current season misclassification. Similar patterns as any influenza were observed against A(H3N2) but not A(H1N1)pdm09 or influenza B, but interpretation of these results is challenging due to lower case counts for the latter analyses leading to less precision. The observed patterns for any influenza were likely driven by A(H3N2) since that subtype comprised 67% of specimens during the influenza seasons included in this study, if one assumes the subtype distribution for unsubtyped specimens is the same as for subtyped specimens. We noted that for patients who were not vaccinated in the current season, residual protection appeared to increase with increasing numbers of vaccines received during previous seasons. We also demonstrated that being vaccinated in the current season resulted in consistently greater protection, compared with not being vaccinated in the current season, regardless of the number of previous vaccinations.

While reduced VE from repeated vaccination has been reported previously \[[@r13],[@r25]\], this has not been consistently found \[[@r11],[@r12]\]. The antigenic distance hypothesis is one potential explanation for reduced VE; if the vaccine strains for the current season and prior season are similar but the current season's vaccine strain is distinct from the current epidemic strain, negative interference leading to reduced VE for the current season may result \[[@r7]\]. However, this hypothesis does not consider the effects of multiple previous vaccine or virus exposures \[[@r25]\]. Thompson et al. \[[@r26]\] examined up to 4 years of previous vaccination history among healthcare workers and observed a greater blunting of serologic response to the A(H3N2) vaccine strain with more doses of previous vaccines received. In addition, two studies have examined vaccination history for up to five previous seasons, with one study observing reduced VE with repeated vaccination \[[@r17]\] while the other did not \[[@r18]\]. However, similar to our results, both studies showed that vaccination in the current season provided some protection against influenza regardless of the number of previous vaccinations. No study has ever examined the impact of repeated vaccination over 10 previous seasons. The residual protection from being vaccinated in previous seasons observed in our study has also been seen elsewhere; this phenomenon may result from cross-reactivity of immune responses elicited by previous vaccinations with current-season virus antigens \[[@r17]\]. It is possible that due to this potential residual protection, the incremental benefit of current season vaccination may be difficult to observe for those who have received many previous vaccinations.

It remains unclear whether true vaccine interference is occurring from repeated vaccination or whether the differences between studies are an artefact of residual confounding \[[@r17]\]. Individuals may be more inclined to be vaccinated for the first time if they were infected by influenza in the prior season. Vaccine responses may be enhanced with recent prior infection \[[@r27]\], such that those who were vaccinated repeatedly may appear to have lower VE. However, measuring immunity arising from previous infection is challenging \[[@r11]\]. In addition, while pooling of multiple seasons can increase statistical power, it can mask important variation at the individual season level \[[@r14]\]. Thus, a large knowledge gap persists regarding the immunologic mechanisms for potential vaccine interference. Future studies that longitudinally ascertain both influenza vaccination and influenza infection status over multiple seasons would be helpful to better understand the impact of repeated vaccination on current season VE as well as residual protection from previous vaccination.

This study has several limitations. First, the specimens were not collected through systematic screening and enrollment but rather as part of routine clinical care. However, we have validated the use of these specimens for estimating VE \[[@r19]\]. Second, while test-negative studies typically use symptom onset date as the index date, we were limited to using specimen collection date. This may have led to underestimation of VE. Third, the VE estimate against unsubtyped influenza A was outside of the range between those against A(H1N1)pdm09 and A(H3N2), raising the possibility of potential bias. Although only 49% of individuals positive for influenza A had their specimens subtyped, they are fairly representative of all individuals positive for influenza A ([Supplementary Table S1](file:///C:\\\\content\\\\10.2807\\\\1560-7917.ES.2020.25.1.1900245#supplementary_data)). We speculate that the lower VE observed for unsubtyped specimens may be due to a greater proportion being collected during the 2014/15 season (a season with known poor match) and during later months of influenza season (with potentially lower VE due to intra-season waning of immunity). Fourth, receipt of influenza vaccines outside of physician offices and pharmacies leads to misclassification of vaccination status when relying on health administrative data to ascertain vaccination status. However, healthcare-seeking behaviour has been found to be similar between test-positive and test-negative individuals \[[@r28]\], so any misclassification would likely be non-differential and underestimate VE, as demonstrated in our sensitivity analyses. The low sensitivity value for the influenza vaccination billing claims used in these sensitivity analyses may have resulted from bias given the self-reported nature of the reference standard available for validation of the claims data, or because pharmacist billing claims data were not yet available for inclusion in the validation study \[[@r22]\]. Fifth, the macro programme used for our sensitivity analysis could not include interaction terms with the main exposure to determine whether subgroup similarities/differences in VE were maintained after misclassification was corrected, and could only correct for misclassification of current season vaccination status and not misclassification in past seasons. However, our sensitivity analyses involving reclassification of past vaccination based on misclassification of current season vaccination status found very similar trends as when accounting only for current season misclassification. Sixth, we used the same values of sensitivity and specificity of the vaccination billing claims for all strata of past vaccination history because we did not have stratum-specific parameters. The observed trend might not remain if the magnitude of the bias correction varies by past vaccination history. Seventh, our use of meta-regression to assess for trends in VE estimates between vaccination history strata does not capture season-to-season heterogeneity in terms of circulating viruses, vaccine match, and host-virus immunological interactions. Eighth, we did not have information on participants' influenza infections in the previous seasons, as most infections do not result in laboratory testing. Ninth, we did not have information on vaccination history for \> 10 previous influenza seasons; the impact of repeated vaccination over longer periods of time remain unknown. Finally, as an observational study, the possibility of residual confounding remains.

Conclusions
===========

In summary, we observed modest VE for community-dwelling older adults in Ontario, Canada during the 2010/11 to 2015/16 influenza seasons. We observed declining VE associated with repeated vaccination, however current season vaccination likely provides some protection against influenza regardless of the number of vaccines received over the previous 10 influenza seasons. Moreover, among those not vaccinated in the current season, increasing residual protection was observed with increasing numbers of previous vaccines received. Therefore, until effective universal influenza vaccines are available and eliminate the need for annual influenza vaccination, our findings support current recommendations for annual vaccination among older adults given their higher risk for influenza-related morbidity and mortality.
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